Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection

Table 4 Adverse events overview

Adverse events	2DR	3DR	P value
Agrypnia^a	0 (0%)	3 (10.71%)	0.236
Anxiety/depression^a	1 (3.70%)	1 (3.5%)	1
Loss of appetite^a	1 (3.70%)	3 (10.71%)	0.63
Diarrhea/celialgia^a	1 (3.70%)	2 (7.14%)	0.97
Nausea^a	1 (3.70%)	2 (7.14%)	0.97
Vomiting^a	0 (0%)	5 (17.86%)	0.051
Fatigue^a	4 (14.81%)	3 (10.71%)	1
Dizzy^a	2 (7.41%)	15 (53.57%)	0.009
Upper respiratory tract infection^a	4 (14.81%)	3 (10.71%)	1
Rash^a	6 (22.22%)	9 (28.57%)	0.589
SAEs	0 (0%)	5 (15.15%)	0.058

ISSN: 1471-2334